| Founded | 2019 |
|---|---|
| Closed | 2023 |
| Country | USA |
| Sector | Biotech |
| Total raised | ~$1.8B (a16z, ARCH Venture Partners, Casdin Capital, GV) |
| Collapse type | Slow Death |
| Founder | Alexis Borisy, Sandra Horning |
EQRx
"The biotech that raised $1.8 billion promising to sell cancer drugs at 90% off list price — then failed its clinical trials, collapsed its SPAC valuation from $3.4B to near zero, and merged away"
Years-long decline before final shutdown
Key Events Timeline
EQRx was founded in 2019 by Alexis Borisy — a prolific biotech entrepreneur and investor — and Sandra Horning, the former Chief Medical Officer of Genentech, with a genuinely ambitious mission: develop or license lower-cost versions of expensive cancer drugs and bring them to market at prices 80-90% below standard US list prices.
// full analysis
Full analysis requires the Analyst plan
Documented cause · Market cycle · Competitive moat type · Verified lesson
€149/mo · or contribute your autopsy for free access →
UnicornBurn Season 0 opens July 2026. 10,000 founders competing in one world. Your startup fights for the market every Saturday. Most will end up here. Which one are you?
JOIN SEASON 0 →EQRx followed a documented pattern. Identify the same signals in any company before they reach the point of no return.
Witnessed a startup failure first-hand? Share the real story. First-hand accounts from founders and team members get prioritized for publication.
SUBMIT AN AUTOPSY →Failure intelligence for due diligence and risk analysis.
Structured dataset by collapse type, for 5031 startups. 7-day trial.
See plans →Free JSON API. No key required. 50 autopsies, 10 req/day.
Full dataset available with Intelligence plan API key. CORS enabled.
Explore API →Academic, press, or research use? Free JSON API available — no auth required →